Key Points
- Illumina director Keith Meister sold 220,000 shares for about $33.5 million at an average price of $152.27, cutting his stake by 6.29% while still holding more than 3.28 million shares.
- Illumina reported stronger-than-expected quarterly results, with EPS of $1.15 and revenue of $1.09 billion, both topping analyst estimates; revenue rose 4.8% year over year.
- Analyst sentiment remains mixed but constructive: the stock carries a consensus “Hold” rating, though several firms recently raised targets or reiterated bullish views, and the average price target is $138.38.
Illumina, Inc. (NASDAQ:ILMN - Get Free Report) CAO Scott Ericksen sold 500 shares of Illumina stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the sale, the chief accounting officer directly owned 14,446 shares of the company's stock, valued at approximately $2,311,360. This trade represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Illumina Stock Up 0.9%
Shares of Illumina stock opened at $164.40 on Tuesday. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12 month low of $78.79 and a 12 month high of $165.97. The business has a fifty day simple moving average of $134.48 and a 200 day simple moving average of $132.39. The stock has a market cap of $24.87 billion, a PE ratio of 29.89, a price-to-earnings-growth ratio of 2.70 and a beta of 1.42.
Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to analysts' expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts predict that Illumina, Inc. will post 5.2 EPS for the current year.
Wall Street Analyst Weigh In
Several research firms have weighed in on ILMN. Canaccord Genuity Group reduced their target price on Illumina from $150.00 to $140.00 and set a "hold" rating on the stock in a report on Friday, May 1st. Citigroup lifted their target price on Illumina from $80.00 to $95.00 and gave the stock a "sell" rating in a report on Monday, May 4th. Wall Street Zen lowered Illumina from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 9th. Robert W. Baird set a $137.00 target price on Illumina in a report on Friday, February 6th. Finally, Evercore reiterated an "outperform" rating on shares of Illumina in a report on Friday, May 1st. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $138.38.
Read Our Latest Report on Illumina
Illumina News Summary
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and kept a Buy rating, signaling continued confidence in the company’s upside potential and valuation. Benzinga article
- Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are now optimized on Illumina software, which could support broader adoption of Illumina’s ecosystem and strengthen its positioning in cancer research tools. Business Wire article
- Neutral Sentiment: Chief accounting officer Scott D. Ericksen sold a small number of shares under a pre-arranged Rule 10b5-1 plan; while routine, it adds to recent insider selling activity. SEC filing
- Negative Sentiment: Director Keith A. Meister sold a very large block of Illumina shares in multiple transactions around May 28-June 1, reducing his stake materially. Large insider sales can weigh on sentiment even when they do not necessarily reflect operational weakness. SEC filing
Institutional Trading of Illumina
Institutional investors and hedge funds have recently bought and sold shares of the stock. Elyxium Wealth LLC acquired a new position in Illumina during the fourth quarter worth approximately $25,000. Board of the Pension Protection Fund acquired a new position in Illumina during the fourth quarter worth approximately $26,000. Creative Capital Management Investments LLC increased its position in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company's stock worth $26,000 after buying an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in Illumina during the fourth quarter worth approximately $26,000. Finally, Laurel Wealth Advisors LLC acquired a new position in Illumina during the fourth quarter worth approximately $26,000. Institutional investors own 89.42% of the company's stock.
Illumina Company Profile
(
Get Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
